Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54.9M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
34.9M
-
Shares change
-
+388K
-
Total reported value, excl. options
-
$825M
-
Value change
-
+$9.8M
-
Number of buys
-
26
-
Number of sells
-
-29
-
Price
-
$23.83
Significant Holders of Stoke Therapeutics, Inc. - Common Stock (STOK) as of Q2 2020
76 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock as of Q2 2020.
Stoke Therapeutics, Inc. - Common Stock (STOK) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.9M shares
of 54.9M outstanding shares and own 63.66% of the company stock.
Largest 10 shareholders include Apple Tree Partners IV, L.P. (16.8M shares), RTW INVESTMENTS, LP (3.54M shares), Redmile Group, LLC (2.5M shares), Cormorant Asset Management, LP (1.7M shares), GILDER GAGNON HOWE & CO LLC (1.57M shares), VANGUARD GROUP INC (1.28M shares), BlackRock Inc. (1.21M shares), RA CAPITAL MANAGEMENT, L.P. (1.12M shares), FEDERATED HERMES, INC. (830K shares), and FMR LLC (772K shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.